Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6959365 | 0.84 | PSMB1 (0.37) | KDM4EPSMB1PSMB5HTTALDH1A1 | |
| SCHEMBL6977469 | 0.84 | PSMB1 (0.37) | KDM4EPSMB1PSMB5HTTALDH1A1 | |
| SCHEMBL6957764 | 0.82 | PSMB1 (0.40) | KDM4EPSMB1PSMB5ALDH1A1KMT2A | |
| SCHEMBL6955131 | 0.82 | RAB9A (0.33) | MEN1KMT2A | |
| SCHEMBL6978681 | 0.79 | PSMB1 (0.39) | KDM4EPSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL6959426 | 0.77 | PSMB1 (0.33) | KDM4EPSMB1PSMB5HTTALDH1A1 | |
| SCHEMBL9975277 | 0.77 | PSMB1 (0.41) | KDM4EPSMB1PSMB5ALDH1A1PSMB2 | |
| SCHEMBL13151498 | 0.77 | PSMB1 (0.41) | KDM4EPSMB1PSMB5ALDH1A1PSMB2 | |
| Hydrochloric Acid SCHEMBL28035282 | 0.76 | PSMB1 (0.41) | KDM4EPSMB1PSMB5HTTALDH1A1 | |
| SCHEMBL6958662 | 0.75 | PSMB1 (0.35) | PSMB1PSMB5HTTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | KDM4E 2805/4885PSMB1 2822/4885PSMB5 2481/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | KDM4E 2805/4885PSMB1 2822/4885PSMB5 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.